专注癌症未满足医疗需求的全球生物制药领军者亚盛医药-B今日宣布，成功完成一项重大海外配售定价。此次配售发行2200万股普通股，每股定价68.60港元。总收益预计达15.092亿港元，约合1.923亿美元。配售由公司首席执行官杨大俊的关联方大俊杨王朝信托承销，获得高达8倍超额认购，凸显市场强劲信心。公司计划将净资金用于商业化推广、提升患者可及性、加速核心候选药物的全球临床开发、强化全球运营基础设施以及补充营运资金。该配售预计在短期内正式关闭。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.